Stay updated on IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial
Sign up to get notified when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.

Latest updates to the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page
- Check7 days agoChange DetectedThe record history adds a 'Results Posted' entry and updates multiple results-related sections (Outcome Measures, Adverse Events, Baseline Characteristics, Participant Flow, IPD Sharing, Study Description/Design) with a new version dated 2025-11-14, replacing the previous 'Results Submitted' entry.SummaryDifference0.6%

- Check14 days agoChange DetectedThe page history shows a new revision v3.3.2 added and the previous revision v3.3.1 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedThe latest version adds a 'Results Submitted' entry and removes 'No Results Posted' in the History. It is labeled Revision: v3.3.1.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved a site-wide operating-status notice about government funding and NIH/Clinical Center status (including links to cc.nih.gov and opm.gov). The notice previously appeared at the top of the page.SummaryDifference0.2%

- Check43 days agoChange DetectedThe page history shows a long series of version updates with repeated Study Status changes spanning 2018 to 2025, along with occasional edits to the study description, eligibility criteria, and outcome measures.SummaryDifference0.0%

- Check71 days agoChange DetectedKey updates: version bump to v3.2.0 and an important government-operating-status notice; the previous v3.1.0 reference was removed. Overall, user-facing status and versioning information were updated. If no other content changed, this is a targeted update to status and versioning.SummaryDifference7%

Stay in the know with updates to IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IL-15 Combo with Nivolumab & Ipilimumab in Refractory Cancers Clinical Trial page.